All In Biotech

Drug Trial Radar · NCT05348876

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 3, 2022

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that keeps progressing even when the amount of male sex hormones like testosterone (also called androgens) is reduced to very low levels. To reduce androgen levels in prostate cancer patients, androgen deprivation therapy (ADT) is often used. As androgens stimulate the growth of prostate cancer cells, low levels are needed to reduce or slow the growth of these tumors. In men with nmCRPC, the cancer worsens despite low testosterone levels (also called castration resistant). Prostate-specific antigen (PSA) is a protein that is made by both normal cells and by cancerous cells in the body. Thus, PSA levels can be taken as a marker for prostate cancer development. Men with nmCRPC usually have higher levels of (PSA) than normal. They are considered "high risk" if they show signs of quickly increasing PSA levels as this could mean that the tumor is growing and might spread to other parts of the body. The study treatment darolutamide is already available in certain countries for doctors to prescribe to men with prostate cancer that has not yet spread to other parts of the body. It works by blocking androgens from attaching to proteins in cancer cells in the prostate. Results of a previous study in men with high-risk nmCRPC who received darolutamide in addition to ADT are already available, but this study had no Indian patients and was not conducted in India. Therefore, the main purpose of this study is to learn how safe darolutamide is when taken in addition to ADT in Indian participants with high-risk nmCRPC. To answer this question, the researchers will collect all medical problems the participants have that arise during the study and that may or may not be related to the study treatment. These medical problems are also known as "adverse events" (AE). The following information regarding safety of darolutamide will be collected during the study: * the number and severity of AEs that are non-serious or serious * the number of participants who have to permanently stop the treatment due to AEs * the number of participants who have to change the amount of study drug taken due to AEs AEs can be: * abnormal results of laboratory tests, physical examinations, or heart health examinations using ECG (detects heart problems by measuring the electrical activity generated by the heart as it contracts). * relevant changes in vital signs * relevant changes of the participant's daily living abilities (ECOG performance status) These results will then be compared with the results from the previous study to identify any differences for this group of participants. In addition, researchers will collect and compare data on how well darolutamide worked under real world conditions in this group of participants. All participants will take darolutamide as tablets by mouth twice a day. The participants will visit the study center at the start of the study, and then every 16 weeks until their cancer gets worse, they develop medical problems, they leave the study or until the study is terminated. During the study, the study team will * take blood and urine samples * do physical examinations * check vital signs * examine heart health using ECG * assess the participant's ECOG performance status * ask the participants questions about how they are feeling and what AEs they are having. If the trial is stopped, participants may have the option to continue to receive darolutamide, provided they benefit from the treatment

Conditions

  • Non-metastatic Castration-resistant Prostate Cancer

Interventions

  • Darolutamide (Nubeqa, BAY1841788)Drug

    600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity.Time frame: Approximately 15 months.
  2. Number of participants with discontinuations of study treatment due to AEsTime frame: Approximately 15 months
  3. Number of participants with dose modifications of study treatment due to AEsTime frame: Approximately 15 months
  4. Number of participants with clinically significant abnormalities in laboratory parametersTime frame: Approximately 15 months
  5. Number of participants with clinically significant electrocardiograms abnormalitiesTime frame: Approximately 15 months
  6. Number of participants with clinically significant physical examination abnormalitiesTime frame: Approximately 15 months
  7. Number of participants with clinically significant changes in vital signsTime frame: From baseline to approximately 15 months
  8. Number of participants with changes in eastern cooperative oncology group (ECOG) performance statusTime frame: From baseline to approximately 15 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)

    Nadiād, Gujarat, India · Recruiting

  • HCG Oncology Center

    Bengaluru, Karnataka, India · Recruiting

  • Amrita Institute of Medical Sciences

    Kochi, Kerala, India · Recruiting

  • Regional Cancer Centre - Thiruvananthapuram

    Thiruvananthapuram, Kerala, India · Recruiting

  • MVR Cancer Centre and Research Institute

    Vellalasseri, Kerala, India · Recruiting

  • Sujan Surgical Cancer Hospital & Amravati Cancer Foundation

    Amravati, Maharashtra, India · Active not recruiting

  • Tata Memorial Hospital

    Mumbai, Maharashtra, India · Recruiting

  • Dr. RML Hospital & PGIMER

    New Delhi, National Capital Territory of Delhi, India · Completed

  • Rajiv Gandhi Cancer Institute & Research Centre

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • All India Institute of Medical Sciences

    Bhubaneswar, Odisha, India · Recruiting

  • Jawaharlal Institute Of Postgraduate Medical Education and R

    Gorimedu, Puducherry, India · Not yet recruiting

  • Bhagwan Mahaveer Cancer Hospital & Research Centre

    Jaipur, Rajasthan, India · Recruiting

  • Apollo Research Foundation

    Hyderabad, Telangana, India · Not yet recruiting

  • Mahamana Pandit Madan Mohan Malviya Cancer Centre

    Varanasi, Uttar Pradesh, India · Recruiting

  • Netaji Subhas Chandra Bose Cancer Hospital

    Kolkata, West Bengal, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.